Press release
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market
Introduction
GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive.
However, the last decade has witnessed a surge in research activity and clinical trials focused on gene therapy, enzyme replacement therapy (ERT), and small molecule approaches. Global pharmaceutical and biotech companies are investing heavily in rare disease R&D, fueled by orphan drug designations, fast-track approvals, and patient advocacy initiatives.
The global GM1 Gangliosidosis market, valued at USD $360 million in 2024, is projected to reach USD $1.2 billion by 2034, growing at a CAGR of 12.5%. This growth reflects the combination of rising awareness, expanding access to genetic testing, and a strong therapeutic pipeline.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70789
Market Overview
• Market Size (2024): USD $360 million
• Forecasted Market Size (2034): USD $1.2 billion
• CAGR (2024-2034): 12.5%.
• Key Drivers: Advances in gene therapy, orphan drug incentives, growing patient advocacy, and rising genetic screening.
• Key Challenges: Small patient pool, high R&D costs, and limited availability of specialized treatment centers.
• Leading Players: Passage Bio, Axovant Gene Therapies (Sio Gene Therapies), Lysogene, Esteve, Orphazyme, among others.
The market is still emerging but highly innovation-driven, with collaborations between biotech firms, research institutes, and healthcare organizations fueling clinical development.
Segmentation Analysis
By Therapy Type
• Gene Therapy
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Small Molecule Therapies
• Supportive & Symptomatic Care
By Drug Class
• Viral Vector-Based Therapies (AAV, Lentivirus)
• Recombinant Enzymes
• Pharmacological Chaperones
• Experimental Pipeline Agents
By Patient Group
• Infantile GM1
• Juvenile GM1
• Adult GM1
By End Use
• Hospitals & Specialty Clinics
• Research Institutes
• Genetic Counseling Centers
By Distribution Channel
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
Segmentation Summary:
Gene therapy dominates the pipeline, with AAV-based approaches showing promising results in early trials. Enzyme replacement therapy is another active area of development. Infantile GM1 represents the highest unmet need due to rapid disease progression and limited treatment windows.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70789/gm1-gangliosidosis-market
Regional Analysis
North America
• Largest market, led by the U.S., where most gene therapy trials are concentrated.
• Strong support through FDA orphan drug incentives and patient advocacy foundations.
Europe
• Significant activity in rare disease research across Germany, France, and the UK.
• EMA provides accelerated pathways for orphan drugs, boosting biotech participation.
Asia-Pacific (APAC)
• Fastest-growing region, with improving access to genetic testing and rising interest in rare disease therapies in Japan, China, and India.
• Government initiatives supporting orphan drug access are expanding.
Middle East & Africa (MEA)
• Limited market penetration due to healthcare infrastructure challenges.
• Growing awareness and diagnostic capabilities in select urban centers.
Latin America
• Brazil and Mexico emerging as key markets for clinical trials and genetic screening initiatives.
Regional Summary:
North America and Europe lead in research and revenue share, while Asia-Pacific is expected to post the highest CAGR through 2034 due to rising awareness and expanding biopharma investments.
Market Dynamics
Key Growth Drivers
• Rising genetic testing and early diagnosis rates.
• Growing clinical trial pipeline for gene and enzyme replacement therapies.
• Orphan drug status and government incentives for rare diseases.
• Increasing role of patient advocacy organizations in awareness and funding.
Key Challenges
• Ultra-rare prevalence limits commercial returns.
• High therapy costs (often above USD 1 million per patient for gene therapies).
• Recruitment challenges for large-scale clinical trials.
• Lack of standardized global treatment protocols.
Latest Trends
• AAV-based gene therapies progressing into clinical phases.
• Expansion of substrate reduction therapies as adjunct treatments.
• Development of global patient registries for better data collection.
• Increased collaborations between biotech and academic institutions.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70789
Competitor Analysis
Major Players in the GM1 Gangliosidosis Market:
1. Passage Bio, Inc.
2. Sio Gene Therapies (Axovant)
3. Lysogene S.A.
4. Esteve Pharmaceuticals
5. Orphazyme A/S
6. Novartis AG (rare disease division)
7. Bluebird Bio, Inc.
8. Sarepta Therapeutics, Inc.
9. Genzyme (Sanofi)
10. Pfizer Inc. (gene therapy research)
11. Amicus Therapeutics, Inc.
12. Takeda Pharmaceutical Company
13. BioMarin Pharmaceutical Inc.
14. Abeona Therapeutics, Inc.
15. Orchard Therapeutics plc
Competitive Summary:
The market is dominated by biotech innovators focused on rare diseases, with Passage Bio and Sio Gene Therapies leading the pipeline. Big pharma companies are entering through acquisitions and partnerships. Strategic collaborations, accelerated regulatory designations, and fundraising for clinical advancement are key competitive strategies.
Conclusion
The GM1 Gangliosidosis Market is at the cusp of transformative growth, driven by gene therapy breakthroughs, increasing diagnostic awareness, and supportive rare disease policies. While challenges around affordability and trial recruitment remain, the next decade will see critical progress in treatment availability.
This report is also available in the following languages : Japanese (GM1ガングリオシドーシス市場), Korean (GM1 강글리오사이드증 시장), Chinese (GM1神经节苷脂沉积症市场), French (Marché de la gangliosidose à GM1), German (GM1-Gangliosidose-Markt), and Italian (Mercato della gangliosidosi GM1), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70789
Our More Reports:
Neuroendocrine Tumors (NETs) Market
https://exactitudeconsultancy.com/reports/71255/neuroendocrine-tumors-nets-market
Neurofibrosarcoma Market
https://exactitudeconsultancy.com/reports/71256/neurofibrosarcoma-market
Non-Hodgkin's Lymphoma Market
https://exactitudeconsultancy.com/reports/71257/non-hodgkin-s-lymphoma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM1 Gangliosidosis Market Massive Growth opportunity Ahead here
News-ID: 4148018 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for GM1
GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood.
Download Full PDF Sample Copy of Market Report…
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction
The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant…
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years.
DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover…
GM1 Gangliosidosis Treatment Market
The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:
Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.
Market Dynamics:
Drivers:
Government Investments…
GM1 Gangliosidosis Treatment Market Analysis, Status and Business Outlook 2021 t …
Dec 07, 2021 (Market Intelligence Data) --Global GM1 Gangliosidosis Treatment Market Size, Status, and Forecast 2021-2026. In-depth research accumulated to offer Latest insights about acute features of the global GM1 Gangliosidosis Treatment market. This report provides a detailed overview of key factors in the GM1 Gangliosidosis Treatment Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. The impact of the COVID-19 outbreak on the industry was…
GM1 Gangliosidosis Treatment Market Higher Mortality Rates by 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry…
